Universal CAR-T Cell Therapy for NHL
ConditionNon-hodgkin Lymphoma,B Cell
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBioray Laboratories
About this trial
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Willing to participate in this clinical study and sign an informed consent form;
Age ≥ 18 years old;
Estimated survival time ≥ 3 months;
At least one measurable lesion;
Disqualifiers
Pregnant or lactating women;
Subjects who previously received allogeneic cell therapies, including allogeneic stem cell transplant;
Subjects who previously received anti-CD19 targeted therapy;
Prior treatment with any CAR-T cell product or other genetically modified T cell therapies;
Trial design
Design model
Single group
Treatments tested in this trial
BRL-301
DrugThe administered dose is 5×10\^6/kg
Treatment groups
6 Participants
are divided into 1 treatment groupGroup A: Treatment groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
DLT
The number and severity of dose-limiting toxicity (DLT) events
Time frame
Within 28 Days After BRL-301 InfusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Bioray Laboratories
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Collaborator
Source ClinicalTrials.gov